Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesErasca Inc

Erasca Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
15.25 USD 0.84 ( 5.83%)
Last update at 2026-11-09T15:47:00Z
VOLUME
947578
Market Cap
6965.02M

Momentum Score

…

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
14.13
Low
15.25
High
52 Week Price Range
1.06
Low
23.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Erasca Inc is a clinical-stage biopharmaceutical company developing targeted therapies for genetically defined cancers. Long-term growth drivers include clinical progress across its pipeline, biomarker-driven patient selection, and potential collaborations or approvals that could support commercialization. Investors may find the company attractive because its focused pipeline appears positioned to address unmet needs in selected tumor subsets.
Material risks include high clinical and regulatory execution risk, substantial capital requirements that may lead to dilution, and strong competition in oncology drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
14.41
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.14
ROE
-33.27%
Net Debt
-26.67M
ROCE
-35.74%
Diluted EPS TTM
-0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -124.55M -161.65M -125.04M -242.81M -122.76M
Net income -124.55M -161.65M -125.04M -238.16M -150.09M
Selling general administrative 38.55M 41.73M 37.70M 32.99M 22.62M
Selling and marketing expenses - - 3.73M - -
Gross profit -3.11M -3.81M -3.73M - -
Reconciled depreciation 3.11M 3.81M 3.72M 2.64M 0.83M
Ebit -131.41M -157.09M -125.04M -247.45M -124.88M
Ebitda -128.30M -153.28M -121.31M -43.45M -68.19M
Depreciation and amortization 3.11M 3.81M 3.73M 204.00M 56.69M
Non operating income net other - - - -0.26M 1.93M
Operating income -131.41M -179.59M -141.53M -247.45M -124.88M
Other operating expenses 131.41M 179.59M 141.53M 145.45M 96.54M
Interest expense - - - 201.36M 55.86M
Interest income 16.61M 20.09M 15.35M 4.90M 0.19M
Net interest income 16.61M 20.09M 15.35M 4.90M 0.19M
Non recurring - - - 102.00M 10.85M
Income tax expense - - - -4.64M 27.33M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 128.30M 179.59M 137.79M 145.45M 96.54M
Cost of revenue 3.11M 3.81M 3.73M - -
Total other income expense net 6.86M 17.94M 16.48M 4.64M 2.12M
Net income from continuing ops -124.55M -161.65M -230.59M -242.81M -122.76M
Net income applicable to common shares - - - -242.81M -122.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 396.15M 502.53M 395.30M 514.91M 501.42M
Other current assets 7.66M 10.48M 8.33M 8.88M 5.54M
Total liab 70.98M 79.03M 78.61M 103.06M 44.89M
Total stockholder equity 325.17M 423.50M 316.69M -480.97M -238.17M
Other current liab 22.46M 21.30M 20.19M 24.34M 2.88M
Common stock 0.03M 0.03M 0.01M 0.01M 0.01M
Capital stock 0.03M 0.03M 0.01M 0.01M 0.01M
Retained earnings -892.21M -767.66M -606.01M -480.97M -238.17M
Other liab - - - 0.57M 0.16M
Other assets - - - 5.18M 53.63M
Cash 73.81M 67.74M 93.08M 284.22M 360.49M
Total current liabilities 28.51M 31.39M 26.16M 48.69M 26.38M
Current deferred revenue - - - - 18.54M
Net debt -26.67M -15.85M -37.22M -229.12M -341.70M
Short term debt 5.07M 9.24M 3.97M 1.30M 0.28M
Short long term debt total 47.14M 51.89M 55.86M 55.10M 18.79M
Other stockholder equity 1216.72M 2381.46M 922.61M 1.03M -501.26M
Property plant equipment - - - 24.82M 15.95M
Total current assets 286.24M 308.79M 320.68M 444.50M 420.02M
Long term investments 65.72M 142.16M 9.64M 0.00M 44.77M
Net tangible assets - - - 411.85M 456.53M
Short term investments 202.27M 230.57M 219.28M 151.40M 53.99M
Net receivables 2.50M 2.30M - - 0.10M
Accounts payable 0.98M 0.47M 2.00M 23.05M 4.68M
Accumulated other comprehensive income 0.63M 0.41M 0.08M -1.04M -0.16M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -480.97M -238.17M
Non currrent assets other 1.45M 2.62M 4.38M 5.18M 3.32M
Non current assets total 109.92M 193.73M 74.62M 70.41M 81.40M
Capital lease obligations 47.14M 51.89M 55.86M 55.10M 18.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 110.05M -156.62M -100.63M -52.53M -45.70M
Change to liabilities - - - 0.68M 13.20M
Total cashflows from investing activities 100.42M -156.62M -91.22M -71.08M -64.59M
Total cash from financing activities 1.10M 240.70M 1.29M 98.08M 439.40M
Change to operating activities - - - 15.11M 6.36M
Net income -124.55M -161.65M -125.04M -242.81M -122.76M
Change in cash 6.07M -25.34M -191.14M -76.27M 295.21M
Begin period cash flow 68.15M 93.48M 284.62M 360.89M 65.69M
End period cash flow 74.21M 68.15M 93.48M 284.62M 360.89M
Total cash from operating activities -95.45M -109.42M -101.22M -103.26M -79.60M
Issuance of capital stock 0.00M 239.06M 0.00M 95.25M 436.39M
Depreciation 3.11M 3.81M 3.73M 2.64M 0.83M
Other cashflows from investing activities -9.50M -22.50M -20.00M -4.00M -7.68M
Sale purchase of stock 0.72M 0.80M 0.79M 0.82M 1.07M
Other cashflows from financing activities 1.10M 1.64M 1.29M 2.00M 121.33M
Change to netincome - - - 122.11M 19.18M
Capital expenditures 0.13M 22.56M 1.77M 16.55M 18.89M
Cash flows other operating - - - 15.11M 9.85M
Cash and cash equivalents changes - - - -76.27M 295.21M
Change in working capital -3.33M 1.74M 0.81M 15.79M 7.71M
Stock based compensation 24.90M 26.97M 26.23M 20.11M 8.33M
Other non cash items 4.41M 19.72M -6.95M 101.01M 27.81M
Free cash flow -95.58M -131.98M -102.99M -119.81M -98.48M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ERAS
Erasca Inc		 0.84
5.83%		 15.25 - - - 21.42 -1.57
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

3115 Merryfield Row, San Diego, CA, United States, 92121

858 465 6511

https://www.erasca.com

103

Name Title Year Born
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO 1972
Mr. Ebun S. Garner J.D., Esq. Gen. Counsel & Corp. Sec. 1972
Dr. Wei Lin M.D. Chief Medical Officer 1970
Dr. Michael D. Varney Ph.D. Chairman of R&D, Scientific Advisory Board Member and Director 1958
Dr. David M. Chacko M.D. Chief Financial Officer 1984
Dr. Nik Chetwyn Ph.D. Sr. VP of Operations NA
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer NA
Mr. Brian L. Baker CPA, M.S., MS, CPA Sr. VP of Fin. 1967
Ms. Chandra D. Lovejoy Sr. VP of Regulatory Affairs 1971
Dr. Robert Shoemaker Ph.D. Sr. VP of Research 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…